Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 06, 2019 02:18 ET | Source: LIDDS AB

LIDDS: Final patient enrolled in Phase IIb Liproca® Depot prostate cancer study

The last patient has been enrolled in LIDDS Phase IIb study for the localized treatment of prostate cancer. The Phase IIb study will identify the optimal dose for Phase III and test the safety of...
February 28, 2019 02:40 ET | Source: LIDDS AB

LIDDS Bokslutskommuniké 2018

OKTOBER - DECEMBER 2018 Nettoomsättningen uppgick till 0,0 (0,4) KSEK Kostnaderna uppgick till 5,0 (2,6) MSEK Resultatet före och efter skatt uppgick till -4,9 (-2,2) MSEK ...
February 06, 2019 03:08 ET | Source: LIDDS AB

LIDDS employs Head of Clinical Development

LIDDS has employed Charlotta Gauffin as Head of Clinical Development. Charlotta will join the company in March 2019 and be responsible for the Phase IIb clinical study for Liproca® Depot and the...
February 05, 2019 03:39 ET | Source: LIDDS AB

LIDDS adds another Scandinavian clinic to the NZ-DTX-001 clinical trial

UPPSALA, SWEDEN - LIDDS AB (publ) has received approval from the Danish Medicines Agency (DKMA) to conduct its Phase I NZ-DTX-001 clinical trial. The Danish study is in addition to the Phase I...
February 04, 2019 07:21 ET | Source: LIDDS AB

LIDDS research activities in intratumoral immunotherapy are in line with leading oncology expert recommendations

The European Society for Medical Oncology (ESMO) sponsored paper provides recommendations on the harmonization of methodologies, definitions and data collection that supports LIDDS research into...
January 10, 2019 05:11 ET | Source: LIDDS AB

LIDDS employs Head of Business Development

LIDDS announces today that Markus Thor has been appointed as Head of Business Development and will join the company in March 2019. The employment is a consequence of the enlarged project portfolio...
November 29, 2018 02:45 ET | Source: LIDDS AB

LIDDS Delårsrapport juli - september 2018

JULI - SEPTEMBER 2018 Nettoomsättningen uppgick till 7,8 (0,2) KSEK Kostnaderna uppgick till 2,5 (1,5) MSEK Resultatet före och efter skatt uppgick till 5,4 (-1,5) MSEK Resultat per aktie uppgick...
November 21, 2018 02:45 ET | Source: LIDDS AB

LIDDS adds two major university clinics in Lithuania to speed up enrollment in ongoing Phase IIb study

The National Cancer Institute in Vilnius and the University Clinic of Kaunas are now ready to start inclusion of patients in Part II of the LPC-004 study. Lithuanian authorities have recently...
November 16, 2018 04:08 ET | Source: LIDDS AB

LIDDS participates at Redeye Life Science Day

The Life Science Event takes place at Haymarket by Scandic on November 21. CEO Monica Wallter will present the company and update the audience on the latest developments of the NanoZolid technology...
November 16, 2018 03:51 ET | Source: LIDDS AB

LIDDS participates at Redeye Life Science Day

The Life Science Event takes place at Haymarket by Scandic on November 21. CEO Monica Wallter will present the company and update the audience on the latest developments of the NanoZolid technology...